Fulgent Genetics Stock EBITDA

FLGT Stock

USD 18.33 0.46 2.57%

Fulgent Genetics fundamentals help investors to digest information that contributes to Fulgent Genetics' financial success or failures. It also enables traders to predict the movement of Fulgent Stock. The fundamental analysis module provides a way to measure Fulgent Genetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fulgent Genetics stock.

		Last Reported	Projected for Next Year
	EBITDA	-46.6 M	-44.2 M

EBITDA is likely to gain to about (44.2 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Fulgent Genetics Company EBITDA Analysis

Fulgent Genetics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Fulgent Genetics EBITDA

(46.55 M)

Most of Fulgent Genetics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulgent Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Fulgent EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Fulgent Genetics is extremely important. It helps to project a fair market value of Fulgent Stock properly, considering its historical fundamentals such as EBITDA. Since Fulgent Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fulgent Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fulgent Genetics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Property Plant Equipment	Common Stock	Short Term Investments	Capital Surpluse	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue	Short Term Debt	Short Long Term Debt
Total Assets		1.0	0.99	-0.91	0.98	0.85	0.64	0.88	0.9	0.96	-0.59	0.9	0.98	0.96	0.97	0.9	0.95	0.89	0.79	-0.28
Total Stockholder Equity	1.0		0.99	-0.9	0.99	0.84	0.62	0.87	0.89	0.96	-0.59	0.9	0.98	0.97	0.97	0.89	0.94	0.88	0.78	-0.29
Net Tangible Assets	0.99	0.99		-0.93	0.97	0.82	0.65	0.86	0.87	0.96	-0.6	0.87	0.99	0.98	0.95	0.9	0.95	0.92	0.73	-0.35
Net Debt	-0.91	-0.9	-0.93		-0.85	-0.85	-0.81	-0.88	-0.92	-0.79	0.58	-0.87	-0.9	-0.92	-0.89	-0.97	-0.89	-0.98	-0.76	0.14
Retained Earnings	0.98	0.99	0.97	-0.85		0.77	0.52	0.81	0.86	0.95	-0.48	0.9	0.94	0.96	0.96	0.87	0.9	0.82	0.77	-0.26
Accounts Payable	0.85	0.84	0.82	-0.85	0.77		0.89	0.99	0.93	0.73	-0.6	0.88	0.85	0.73	0.88	0.86	0.89	0.88	0.9	0.02
Net Receivables	0.64	0.62	0.65	-0.81	0.52	0.89		0.87	0.79	0.49	-0.49	0.69	0.68	0.57	0.65	0.77	0.74	0.87	0.73	0.05
Total Liab	0.88	0.87	0.86	-0.88	0.81	0.99	0.87		0.94	0.77	-0.57	0.89	0.88	0.78	0.92	0.88	0.94	0.92	0.88	-0.05
Total Current Assets	0.9	0.89	0.87	-0.92	0.86	0.93	0.79	0.94		0.74	-0.57	0.98	0.85	0.84	0.94	0.97	0.86	0.89	0.95	0.13
Property Plant Equipment	0.96	0.96	0.96	-0.79	0.95	0.73	0.49	0.77	0.74		-0.57	0.75	0.97	0.93	0.89	0.74	0.92	0.8	0.62	-0.51
Common Stock	-0.59	-0.59	-0.6	0.58	-0.48	-0.6	-0.49	-0.57	-0.57	-0.57		-0.51	-0.58	-0.52	-0.54	-0.52	-0.56	-0.55	-0.46	0.16
Short Term Investments	0.9	0.9	0.87	-0.87	0.9	0.88	0.69	0.89	0.98	0.75	-0.51		0.83	0.84	0.94	0.95	0.82	0.82	0.96	0.16
Capital Surpluse	0.98	0.98	0.99	-0.9	0.94	0.85	0.68	0.88	0.85	0.97	-0.58	0.83		0.95	0.93	0.85	0.97	0.92	0.71	-0.41
Long Term Investments	0.96	0.97	0.98	-0.92	0.96	0.73	0.57	0.78	0.84	0.93	-0.52	0.84	0.95		0.92	0.9	0.9	0.89	0.67	-0.35
Net Invested Capital	0.97	0.97	0.95	-0.89	0.96	0.88	0.65	0.92	0.94	0.89	-0.54	0.94	0.93	0.92		0.92	0.94	0.87	0.85	-0.13
Net Working Capital	0.9	0.89	0.9	-0.97	0.87	0.86	0.77	0.88	0.97	0.74	-0.52	0.95	0.85	0.9	0.92		0.85	0.93	0.86	0.04
Capital Stock	0.95	0.94	0.95	-0.89	0.9	0.89	0.74	0.94	0.86	0.92	-0.56	0.82	0.97	0.9	0.94	0.85		0.93	0.73	-0.37
Current Deferred Revenue	0.89	0.88	0.92	-0.98	0.82	0.88	0.87	0.92	0.89	0.8	-0.55	0.82	0.92	0.89	0.87	0.93	0.93		0.73	-0.24
Short Term Debt	0.79	0.78	0.73	-0.76	0.77	0.9	0.73	0.88	0.95	0.62	-0.46	0.96	0.71	0.67	0.85	0.86	0.73	0.73		0.33
Short Long Term Debt	-0.28	-0.29	-0.35	0.14	-0.26	0.02	0.05	-0.05	0.13	-0.51	0.16	0.16	-0.41	-0.35	-0.13	0.04	-0.37	-0.24	0.33

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Fulgent Genetics

Ebitda Over Time

Fulgent Ebitda

Ebitda

(44.22 Million)

At this time, Fulgent Genetics' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Fulgent Genetics reported earnings before interest,tax, depreciation and amortization of (46.55 Million). This is 105.31% lower than that of the Health Care Providers & Services sector and 113.42% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.19% higher than that of the company.

Fulgent EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulgent Genetics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics of similar companies.

Fulgent Genetics is currently under evaluation in ebitda category among its peers.

Fulgent Genetics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fulgent Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fulgent Genetics' managers, analysts, and investors.

Environmental

Governance

Social

Fulgent Genetics Institutional Holders

Institutional Holdings refers to the ownership stake in Fulgent Genetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fulgent Genetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fulgent Genetics' value.

		Shares
Invenomic Capital Management, Lp	2024-09-30	249.7 K
Charles Schwab Investment Management Inc	2024-09-30	245.2 K
Northern Trust Corp	2024-09-30	213.1 K
Bank Of New York Mellon Corp	2024-06-30	201.2 K
Amvescap Plc.	2024-06-30	166.7 K
Jpmorgan Chase & Co	2024-06-30	158.6 K
Barclays Plc	2024-06-30	142.6 K
Bank Of America Corp	2024-06-30	130.7 K
Deutsche Bank Ag	2024-06-30	120.7 K
Blackrock Inc	2024-06-30	3.9 M
Vanguard Group Inc	2024-09-30	1.4 M

Fulgent Fundamentals

	Return On Equity	-0.14
	Return On Asset	-0.0415
	Profit Margin	(0.59) %
	Operating Margin	(0.24) %
	Current Valuation	342.57 M
	Shares Outstanding	30.59 M
	Shares Owned By Insiders	32.33 %
	Shares Owned By Institutions	54.28 %
	Number Of Shares Shorted	645.62 K
	Price To Earning	3.95 X
	Price To Book	0.48 X
	Price To Sales	1.97 X
	Revenue	289.21 M
	Gross Profit	366.9 M
	EBITDA	(46.55 M)
	Net Income	(167.82 M)
	Cash And Equivalents	515.4 M
	Cash Per Share	17.03 X
	Total Debt	15.25 M
	Debt To Equity	0.03 %
	Current Ratio	5.29 X
	Book Value Per Share	37.28 X
	Cash Flow From Operations	27 M
	Short Ratio	4.54 X
	Earnings Per Share	(5.52) X
	Price To Earnings To Growth	1.32 X
	Target Price	27.67
	Number Of Employees	1.18 K
	Beta	1.51
	Market Capitalization	546.59 M
	Total Asset	1.24 B
	Retained Earnings	633.17 M
	Working Capital	434.83 M
	Current Asset	2.93 M
	Current Liabilities	686 K
	Net Asset	1.24 B

About Fulgent Genetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Fulgent Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC